Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 19;4:988. doi: 10.1038/s42003-021-02503-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a The WT and mutated sequences of the human KRAS gene. b ORNs examined as sequence-specific blocking agents and their complementary sequence in the human KRAS gene. c, d Results of RPA blocked by an ORN (ORNi-RPA) using template gDNA extracted from 293T cells, which are WT for KRAS. ORNs targeting human KRAS (ORN_KRAS; K), human CDKN2A (p16) (ORN_p16; p16), chicken Pax5 (ORN_cPax5_Ex1B; P), and an ORN that differs from ORN_KRAS by one nucleotide (ORN_KRAS_mut; Km) were used. Amplified KRAS is indicated by an arrowhead. M, molecular weight marker. e Results of ORNi-RPA of gDNA extracted from HCT116 cells, which have both a WT and mutant (G13D) allele of KRAS. f DNA sequencing analysis of ORNi-RPA products. RPA and ORNi-RPA products in e were purified and sequenced using a forward primer. g Results of ORNi-RPA of gDNA possessing both a WT and mutant (G12D) allele of KRAS. h DNA sequencing analysis of ORNi-RPA products. RPA and ORNi-RPA products in g were purified and sequenced using a forward primer.